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Forthepast50years,qualitycontrolandsafetytestshavebeenusedtoevaluatevaccinesafety.However,conventionalanimalsafety
tests need to be improved in several aspects. For example, the number of test animals used needs to be reduced and the test period
shortened. It is, therefore, necessary to develop a new vaccine evaluation system. In this review, we show that gene expression
patterns are well correlated to biological responses in vaccinated rats. Our ﬁndings and methods using experimental biology and
genome science provide an important means of assessment for vaccine toxicity.
1.Introduction
Vaccinationeﬀectivelyenablesthecontrolofmanyinfectious
diseases. However, we cannot always avoid the problem
of adverse reactions accompanied by vaccination. While
most adverse reactions are mild and local, some vaccines
have been associated with very rare but severe systemic
reactions. Therefore, all vaccines for public use are made in
compliance with Good Manufacturing Practices (GMP) to
prevent safety problems. Furthermore, manufacturers must
submit samples and results of their in-house tests for each
vaccine batch to the national control authorities before
vaccines are released into the market. Among many quality
control tests, conventional animal safety tests are performed
to detect vaccine toxicity because residual vaccine toxicity
has the potential to cause adverse reactions. For example,
the animal body weight change test is the most commonly
used test to evaluate the toxicity of vaccines [1]. Although
a good correlation of the body weight loss with a vaccine’s
toxicity hasbeenshown[2,3],a greaterunderstanding ofthe
molecularmechanisms involved inthe reactionto a vaccines’
toxicity is needed. We, therefore, attempted to measure
animals’ responses to vaccines by determining changes in
gene expression proﬁles.
Gene expression proﬁling is a unique way to characterize
how cells or tissues are aﬀected by abnormal conditions.
The measurement of gene expression levels upon exposure
to toxicants can be used to identify toxic products, and
to provide information about the mechanism of toxicity
[4]. DNA microarray technology has opened the way for
the parallel detection and analysis of expression patterns of
thousands of genes in a single experiment. Furthermore,
the development of high-quality gene arrays has allowed
DNA microarray technology to become a standard tool in
molecular toxicology. Recently, the ﬁeld of toxicogenomics
has validated the concept of gene expression proﬁles as
“signatures” of toxicant classes [5–7]. These signatures
have eﬀectively directed the analytical search for predictive
toxicant biomarkers and they have contributed to the under-
standing of the dynamic responses of molecular mechanisms
associatedwithtoxicresponses.Infact,manystudiesofgene-
expression proﬁles have now been reported in the toxicology
ﬁeld. For example, Hamadeh et al. reported patterns of gene
expression in liver tissue taken from rats exposed to diﬀerent2 Journal of Biomedicine and Biotechnology
chemicals [8]. DNA microarray assays have also been applied
to the analysis of the side eﬀects of medicines [9]. Recently,
the United States Food and Drug Administration (FDA)
and the European Medicines Agency (EMEA) have, either
individuallyortogether,startedtoreviewsubmissionsforthe
qualiﬁcation of biomarkers for medical products for speciﬁc
purposes proposed by industry [10]. The introduction of
pharmacogenomics, or pharmacogenetics, to the evaluation
of medicines is a global trend.
For a better understanding of the molecular toxicology
regarding vaccines, DNA microarray analysis promises to be
an ideal method, as has been the case for pharmaceuticals.
The FDA now encourages the voluntary submission of
genomic data to the FDA outside of the regular review
process [11]. However, no studies similar to those described
above for pharmaceuticals have yet been conducted in
the ﬁeld of vaccines. At the beginning of this review, we
summarized the current eﬀorts used for the control of
vaccine safety using conventional animal tests. We then
referred to our recent eﬀorts using DNA microarray analysis
to identify “genetic signatures” for the toxicants remaining
in vaccines. Since pertussis and inﬂuenza vaccines are among
the most commonly used vaccines, we tried to develop a
system to evaluate the “genetic signatures” of the toxicity of
these vaccines.
2. CurrentVaccine SafetyTest
2.1. Body Weight Change in Vaccinated Animals. To screen
for general toxicity of vaccines, the body weight of vaccine-
treated animals can be analyzed as the general safety test
[12]. Five mL of the vaccine are injected into the peritoneum
of guinea pigs weighing 300–400g, and the weight loss
experienced by the animals is analyzed at days 1, 2, 3, 4,
and 7 after administration. None of the animals should show
any abnormal signs; no statistically signiﬁcant (P = .01)
diﬀerence in weight loss should be observed between the
treated animals and the control group on any observation
day. This test has been applied to a wide variety of vaccines
in a uniﬁed way, and plays an important role in ensuring the
safety and consistency of vaccine batches [12]. For pertussis
vaccine (inactivated whole cell formulation), the eﬀects of
vaccine treatment were also measured using test for toxicity
to mouse weight gain, in addition to the general safety test.
All mice were weighed on days 0, 1, 2, 3, 4, and 7 after
vaccine administration. The criterion for judgment is that
mean body weight 3 days after injection should be no less
thanthatatthetimeofinjectionuponstatisticalanalysis,and
no mice showed any abnormal sign during the observation
periods[12].Whenthereferencevaccine(RE:theinactivated
whole cell pertussis vaccine) was administrated, weight loss
was observed on day 1 after administration (Figure 1(a)).
2.2. Leukocytosis-Promoting Toxicity in Vaccinated Animals.
To detect the toxin present in pertussis vaccines, the number
of peripheral leukocytes can also be analyzed. Pertussis
vaccine is injected into the peritoneum of mice at a
dose of 0.5mL. Leukocytes present in peripheral blood
are then counted 3 days after injection [12]. The white
blood cell (WBC) counts in peripheral blood of reference
vaccine-treated mice reach approximately 2,500 cells/μL
(Figure 1(b)). The standard criterion of safety for pertussis
vaccine (inactivated whole cell formulation) is that the
mean count of leukocytes in peripheral blood, 3 days after
injection, should not exceed 10 times that before injection
[12].
2.3. Leukopenic Toxicity Test in Vaccinated Animals. Quality
control of inﬂuenza vaccines is performed using the general
safety test and the leukopenic toxicity test (LTT), which
is based on peripheral WBC counts in mice 12–18 hours
after intraperitoneal injection of a vaccine. The criterion for
judgment is that the leukopenic toxicity of the test sample
relative to that of the toxicity reference sample should be no
higher than the value corresponding to 80% of the leukocyte
count of the control relative to that of the toxicity reference
sample [12–14].
3.DNA Microarray-BasedSafetyTest
The currently used quality control and safety tests, such
as the LTT and the general safety test, have been used
to evaluate vaccine safety for over 50 years [3]. We are
now developing a new quality control method for vaccines
using DNA microarray analysis as a substitute for the
conventional animal tests [15–17]. The principle of this
method is to translate vaccine quality, immunogenicity,
and reactogenicity, into gene expression proﬁle data. This
method is expected to be informative, rapid, and highly
sensitive.
For DNA microarray analysis using vaccines, 8 week-
old male rats, weighing 180–220g, were intraperitoneally
administered with 5mL of vaccine or physiological saline
(SA). Three to 6 rats were used for each group. Vaccinated
rats were sacriﬁced to obtain whole lung, kidney, brain,
and the lateral left lobe of the liver on day 1, 2, 3, and
4 postadministration (Figure 2) .T i s s u e sw e r ei m m e d i a t e l y
frozen in liquid nitrogen for storage. Thawed tissue was
homogenized and poly(A)
+ RNA was puriﬁed from the
lysate. Cyanine 5-labeled poly(A)
+ RNA was subjected to
DNA microarray analysis. Blood was also collected, however,
this could not be analyzed due to the low quality of puriﬁed
RNA.
For DNA microarray analysis, a set of synthetic polynu-
cleotides (80-mers) representing 11,468 rat transcripts and
including most of the RefSeq genes deposited in the NCBI
database (MicroDiagnostic, Tokyo, Japan) was arrayed on
aminosilane-coated glass slides [18, 19]. Cyanine 5-labeled
poly(A)
+ RNAwascompetitivelyhybridizedontheslidewith
cyanine 3-labeled common reference RNA. Hybridization
signals were measured, processed into primary expres-
sion ratios ([Cyanine 5-intensity obtained from each sam-
ple]/[Cyanine 3-intensity obtained from common reference
RNA]), and then normalized by multiplying normalization
factors calculated for each microarray feature.Journal of Biomedicine and Biotechnology 3
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Figure 1: Safety control tests for pertussis vaccines. (a) Test for toxicity to mouse weight gain. Physiological saline (SA), an inactivated
whole-cell pertussis vaccine (RE), or an acellular pertussis vaccine (PV)-administered mice were weighed on 0, 1, 2, 3, 4, and 7 days
postadministration. Ten mice in each group were used, and the mean changes in body weight are indicated. (b) Leukocytosis promoting
activity of various pertussis vaccines. White blood cell (WBC) counts in peripheral blood were measured 3 days after vaccine administration.
Ten mice in each group were used and the mean WBC counts are indicated.
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Figure 2: The gene expression analysis procedure. The detail of the procedure is described in the text.4 Journal of Biomedicine and Biotechnology
For data processing and hierarchical cluster analysis, the
primary expression ratios were converted into log2 ratios
(log2 Cyanine-5 intensity/Cyanine-3 intensity). The genes
with log2 ratios over 1 or under −1 in at least one sample
were extracted from the primary data matrix, then subjected
to two-dimensional hierarchical cluster analysis for samples
and genes.
For the identiﬁcation of biomarker genes for pertussis
vaccines, we extracted diﬀerentially expressed genes from
physiological saline and pertussis toxin-treated lung samples
using the t-test (P<. 01). Among the extracted genes, we
further selected genes that exhibited mean average log2 ratio
diﬀerences greater than 0.75 between the two sample groups
[17]. For inﬂuenza vaccines, we extracted diﬀerentially
expressed genes from physiological saline and inactivated
whole-virion vaccine-treated lung samples using the t-test
(P<. 005) [16].
4.PertussisVaccines
Pertussis, or whooping cough, is an infectious respiratory
disease caused by a Gram-negative bacillus, Bordetella per-
tussis. Bordetella pertussis possesses several pathogenic com-
ponents, including pertussis toxin (PT) [20]. PT is known
as a leukocytosis promoting factor, a major contributor to
the pathogenesis of pertussis, and an antigen in immunity to
pertussis [21]. At present, whole-cell pertussis vaccines and
acellular pertussis vaccines containing inactivated PT are in
commercial use [20].
Although pertussis vaccines are eﬀective in the preven-
tion of whooping cough, they have occasionally caused local
reactions such as redness, swelling, and pain at the injection
site. However, little is known about the overall responses to
these vaccines. To address this problem, we applied DNA
microarray analysis and quantiﬁcation of speciﬁc genes to
analyze the toxicants in pertussis vaccines [15, 17]. Three
preparations, an acellular vaccine containing inactivated
pertussis toxin (PV), an inactivated whole-cell vaccine (RE),
a n dap u r i ﬁ e dp e r t u s s i st o x i n( P T )w e r ep r e p a r e d .R Ei s
a reference vaccine for National Quality Control Tests of
pertussis vaccines in Japan and is made from formaldehyde-
inactivated Bordetella pertussis preparations. Physiological
saline (SA) was used as a control. For comprehensive gene
expression analysis, 5mL of SA, PV, PT, and RE were each
injected into 3 rats and the vaccinated tissues, lung, brain,
kidney, and liver, were harvested at 1, 2, 3, and 4 days after
vaccine administration. The experiments were performed
twice and puriﬁed poly(A)
+ RNA from a total of 384 samples
was subjected to DNA microarray analysis.
Of the 4 organs tested, the lung expressed genes that
were extracted by DNA microarray analysis were classiﬁed
sharply into clusters depending on sample treatment. From
the DNA microarray analysis of vaccinated rat lungs at day
1, 13 genes for which expression levels were dynamically
changed in response to PT treatment were [17] (accession
numbers were updated in Table 1). Interestingly, the DNA
microarray-based gene expression data correlated well with
thebodyweightchangeofvaccine-treatedmice(Figure 1(a))
and rats [17]. The real-time PCR quantiﬁcation results of
the expression levels of the 13 genes were comparable to
the relative expression ratios from the DNA microarray
analysis. Furthermore, cluster analysis using the 13 genes
could distinguish SA- and PV-treated groups from PT-
and RE-treated groups. These 13 genes are likely to be
closely involved in the toxicity of pertussis vaccines. To
quantify these genes in a convenient way, the QuantiGene
Plex assay was applied. The QuantiGene Plex assay enabled
the simultaneous analysis of the 13 genes. We evaluated
the expression levels of the 13 genes in the lungs of rats
vaccinated with various doses of RE. Nine genes, S100A9,
S100A8, IRF7, MX2, IFI27L, BEST5, MMP9, MMP8,a n d
CYP2E1 (indicated in bold letters in Table 1) showed dose-
dependent up-or down-regulation in response to the various
dosesofREtreatment.REvaccinetoxicitycouldbemeasured
by the expression level in lung lysate of these 9 genes. The
quantiﬁcation of these 9 genes using the QuantiGene Plex
assay is, we believe, a promising candidate for a new control
test for pertussis vaccines.
5. Inﬂuenza Vaccines
Inﬂuenza virus triggers a highly contagious acute respiratory
disease and has caused epidemics and global pandemics,
partly because it possesses the capacity for gradual anti-
genic change in two surface antigens, hemagglutinin (HA)
and neuraminidase (NA) [22]. To combat inﬂuenza, split
vaccines consisting of subvirion preparations and whole-
virus vaccines are manufactured using strains recommended
annually by the WHO, based on the antigenic characteristics
of HAs and NAs. Furthermore, the recent circulation of the
highly pathogenic avian inﬂuenza A (H5N1) virus has raised
concerns about the preparations for a coming inﬂuenza
pandemic [23]. Many eﬀorts are underway to develop
vaccines against inﬂuenza A (H5N1).
To identify biomarkers for inﬂuenza vaccine toxicity, 3
vaccines were used: trivalent inﬂuenza HA vaccine (HAv,
a split vaccine), trivalent inﬂuenza vaccine (WPv, an inac-
tivated whole-virion vaccine), and prepandemic inﬂuenza
vaccine (PDv, inactivated whole-virion (A/H5N1) absorbed
onto an aluminum salt). All were produced by Kaketsuken,
The Chemo-Sero-Therapeutic Research Institute, Japan.
Physiological saline (SA) was used as a control. For com-
prehensive gene expression analysis, SA, HAv, WPv, and
PDv were each injected into 5 rats, and the vaccinated
tissues, lung, liver, brain, and peripheral blood, were har-
vested at 1, 2, 3, and 4 days after vaccine administration.
Puriﬁed poly(A)
+ RNA from a total of 320 samples was
subjected to DNA microarray analysis [16]. Based on the
analysis of pertussis vaccines, described above, the gene
expression proﬁles from lung samples were subjected to two-
dimensional hierarchical cluster analysis. PDv- and WPv-
treated samples at day 1 formed an independent cluster from
other samples, indicating distinct proﬁles in gene expression
of these groups. As was the case with pertussis vaccines,
we tried to identify several biomarkers from the analysis of
lung gene expression. The analysis of lungs from vaccinated
rats at day 1 resulted in the extraction of 76 genes, whose
expression levels were statistically diﬀerent between SA- andJournal of Biomedicine and Biotechnology 5
Table 1 :B i o m a r k e r sf o rp e r t u s s i sv a c c i n et o x i c i t y .
Category Accession no. Symbol Brief description
Inﬂammation
NM 053587 S100A9 A calcium binding protein that may be associated with acute inﬂammatory
processes, coupled with S100a8
NM 053822 S100A8 May play a role in inﬂammatory responses such as cell motility, coupled
with S100a9
NM 019323 MCPT9 A serine protease expressed in mast cells, but the precise function has not
yet been determined
NM 031530 CCL2 A ligand for CCR2 that acts as a chemoattractant of monocytes
IFN inducible,
immune response
NM 001033691 IRF7 Unknown
NM 134350 MX2 Involved in inhibiting vesicular stomatitis virus
NM 203410 IFI27 Induced by steroid hormone, IFN, and LPS in endometrium at
implantation, dendric cells, and macrophases
NM 001007694 IFIT3 May induced by IFN or virus infection
Y07704 BEST5 I n d u c e db yI F Na n di n v o l v e di nb o n ef o r m a t i o n
Peptidoglycan
metabolism
NM 031055 MMP9 Metalloproteinase involved in extracellular matrix remodeling, bone
resorption, and immune responses
NM 022221 MMP8 May play a role in appositional bone formation and regulation of the
extracellular matrix
Xenobiotic
metabolism J02627 CYP2E1 Protects hepatocytes from stress-induced cell death
Others NM 001106862 NGP Unknown
Table 2: Biomarkers for inﬂuenza vaccine toxicity.
Category Accession No. Symbol Brief description
IFN inducible gene
NM 172019 IFI47 Mouse homolog may be a guanine nucleotide-binding protein induced by
IFN-gamma
AF329825 TRAFD1 Putative TRAF-interacting zinc ﬁnger protein
NM 019242 IFRD1 May be involved in proliferation of neuronal and glial precursors
IFN inducible,
immune response
NM 001033691 IRF7 Unknown
NM 134350 MX2 Involved in inhibiting vesicular stomatitis virus
Immune response
NM 172222 C2 Likely component of the classical pathway of the complement cascade
NM 012708 PSMB9 Subunit of the proteasome complex, which may play a role in protein
catabolism
NM 032056 TAP2 Transports peptides into the ER lumen for binding with MHC class I
molecules; plays a role in antigen processing and presentation
NM 033098 TAPBP Facilitates the binding of MHC class I molecules to the transporter
associated with antigen processing (TAP) in MHC class I assembly
NM 017264 PSME1 May play a role in proteasome activation
Chemokine and
Cytokine function
AF065438 LGALS3BP Displays diﬀerential expression in a ﬁbroblast cell line transformed by
human T-cell leukemia virus type 1 Tax protein
NM 012977 LGALS9 A highly selective urate transporter/channel
NM 053819 TIMP1 Acts as an inhibitor of metalloprotease activity; may play a role in vascular
tissue remodeling
NM 023981 CSF1 Plays a role in macrophage formation
NM 145672 CXCL9 Chemokine which plays a role in the recruitment of mononuclear cells and
in allograft rejection
XM 223236 CXCL11 Mouse homolog is a chemokine and is involved in the immune response
Transcription activity AJ302054 ZBP1 DNA binding protein; thought to bind Z-DNA, which is largely controlled
by the amount of supercoiling6 Journal of Biomedicine and Biotechnology
WPv-treated samples (P<. 005) [16]. The cluster analysis
using these 76 genes successfully distinguished WPv- and
PDv-treated groups at day 1 from other groups, indicating
the suitability of the 76 genes as biomarkers for inﬂuenza
vaccines.
The extracted 76 genes were categorized according to
function, such as interferon-inducible, chemokine and
cytokine function, immune response, transcriptional activ-
ity, and so on. Among the 76 genes, 17 genes met the
requirement for high expression levels and were chosen
as representatives for each functional category (Table 2).
Among the 17 genes, IRF7 and MX2 were also nominated
for biomarkers of pertussis vaccine toxicity. Real-time PCR
quantiﬁcation results of the expression levels of the 17 genes
were comparable to the relative expression ratios determined
by DNA microarray analysis. We are now working to estab-
lish a rapid quantiﬁcation system for these 17 biomarkers
using the QuantiGene Plex assay.
6. Japanese EncephalitisVaccines
Japanese encephalitis (JE) is a seasonal and sporadic
encephalitis in East Asia caused by the JE virus. Vaccination
is very important to prevent JE infection, because pallia-
tive care is the only treatment available for JE patients.
Recently, a Vero cell-derived JE vaccine had been licensed
in Japan as an alternative to the long-used mouse brain-
derived JE vaccines. The newly developed Vero cell-derived
vaccine should be at least equivalent to the mouse brain-
derived vaccines, because the mouse brain-derived vaccines
were considered generally safe and succeeded in the near
elimination of JE in certain endemic regions. In this context,
we performed DNA microarray analysis of tissues from
rats administered with mouse brain-derived or Vero cell-
derived JE vaccine and compared the gene expression
proﬁles. As expected, the gene expression patterns in brain
and liver were comparable between mouse brain-derived
and Vero cell-derived vaccines, indicating that both vac-
cines possessed equivalent reactivity characteristics in rats
[24].
7. Conclusions
Over recent decades, the safety control of vaccines has
been assessed using several animal tests, including the body
weight change test and white blood cell counts. However,
conventionalanimalsafetytestsneedtobeimprovedinmany
aspects. For example, the number of test animals used needs
to be reduced and the test period needs to be shortened. This
requiresthedevelopmentofanewvaccineevaluationsystem.
In this review, we showed that gene expression patterns were
well correlated to the biological responsiveness of vaccinated
animals. From the DNA microarray analysis of lungs from
vaccinated rats, we identiﬁed 13 and 17 biomarkers to
detect the toxicity of pertussis and inﬂuenza vaccines,
respectively.
Furthermore,theQuantiGene Plexassayforgeneexpres-
sion analysis is being introduced. The QuantiGene Plex assay
was revealed to be as accurate as real-time PCR and has
the great beneﬁt of being able to evaluate all biomarkers
simultaneously. Using the QuantiGene Plex assay, we could
rapidly and sensitively detect the gene expression changes
that accompany biological reactivity in vaccinated rats.
Thus, it may be concluded that DNA microarray tech-
nology is an informative, rapid, and highly sensitive method
with which to evaluate vaccine quality. Our data suggest that
this new method has the potential to shorten the time for
safety tests and can reduce the number of animals used.
In addition, our test may contribute to the development of
urgently required vaccines. Further analyses are required to
conﬁrm that gene expression changes correlate with vaccine
quality.
In this review, we referred to our recent eﬀorts of
exploring new safety control methods using gene expression
patternindexes,focusingonpertussisandinﬂuenzavaccines.
In the future, for the evaluation of all kinds of vaccines,
microarray analysis is expected to play an important role
in the new safety control test, especially for checking toxin-
reactive transcripts.
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